Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Abnormalities of Motor Imagery and Relationship With Depressive Symptoms in Mildly Disabling Relapsing-Remitting Multiple Sclerosis.
Molecular targets of FTY720 (fingolimod).
Energy Cost of Walking and Its Association With Gait Parameters, Daily Activity, and Fatigue in Persons With Mild Multiple Sclerosis.
Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24weeks of therapy with subcutaneous interferon beta-1a three times weekly.
[Optical coherence tomography in multiple sclerosis].
Ampyra (dalfampridine) medication guide
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Evaluation of sexual function in women at two stages of multiple sclerosis.
Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis.
Validity and Reliability of a Persian Translation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS).
Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial.
Drugs to be Discontinued
"Tell me what you want, what you really really want….": asking people with multiple sclerosis about enhancing their participation in physical activity.
Association mapping of disease loci, by use of a pooled DNA genomic screen.
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.
Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.
Microvesicles: novel biomarkers for neurological disorders.
Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study.
Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial.
A safety and pharmacokinetic study of intravenous natalizumab in patients with MS.
Endogenous opioids regulate the expression of inducible nitric oxide synthase by splenocytes.
Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
On dihydroorotate dehydrogenases, their inhibitors and uses.
Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis.
Complementary and alternative medicine in multiple sclerosis.

Pages